Member Info for daveycaferacer

GA, Barings Aisa et al, surely they are asking serious questions of senior management, whilst the 2 major pieces of bad news are outside the company's control they could have taken some action to mitigate them but a a little subsidiary of CKHH they seem to have a total and complete disregard towards investors. Shameful and it has cost me A LOT of money.

I suspect the company was informed weeks or months ago they needed a US trial but left the bad news until receipt of the CRL. Yet again Investors have been hung out to dry by the company.

what I do not understand is that the Florham Pk Team have been in constant dialogue with the FDA for well over a year, it seems very odd to me that they appear to have been informed right at the end of the process. You would have thought the FDA would have let them know much earlier which is why this smacks of a political/anti-chinese decision and not a clinical one.

I still find it difficult to believe this issue has only just become known through the CRL. What will they do with all the newly recruited sales and marketing people?? Lay them off I guess.

Given the fact the FDA and the Company have been in constant dialogue it seems very odd the goalposts have moved at this late stage. If that’s the FDA stance why didn’t they say so a year ago ….

down 25% on NASDAQ pre-market - now worth less than when it IPO'd on NASDAQ 6 years ago

https://uk.finance.yahoo.com/news/hutchmed-receives-complete-response-letter-100000269.html

In a May 2020 pre-NDA meeting, HUTCHMED reached an agreement with the FDA that the two positive Phase III studies of surufatinib in patients with pNETs and epNETs in China, along with the bridging trial in the U.S. could form the basis to support a U.S. NDA submission.

You would have thought the FDA would have said a year ago they needed a U.S. study when they accepted the bridging study....why wait until now or are they just playing games because Hutchmed is chinese? What are Hutchmed going to do with the sizeable sales and marketing Team in Floreham Park. They effectively have no work to do for the forseable future.

thanks for your insightful updates 1pencil
Let's hope for EMA and FDA approvals in the coming few weeks, a resolution to the HFCAA issue and then a climb back up the greasy pole to a proper valuation of at least 10 x sales (15-20 would be more realistic).........

thanks for your insightful updates 1pencil
Let's hope for EA and FDA approvals in the coming few weeks, a resolution to the HFCAA issue and then a climb back up the greasy pole to a proper valuation of at least 10 x sales (15-20 would be more realistic).........

for the first time ever you couldn't take part in the call unless you had previously registered with your Broker and mine, AJ Bell failed to take the necessary action in time with Computashare so I could not attend. For the past 10+ years I had some very fruitful conversations with Christian and will miss those discussions. For the past 2 years they had an Analyst call after the AGM but not this year. Is that a sign they are now not particularly interested in IR and their investors, other than CKHH? Will they now revert to thinking of themselves as a subsidiary of CKHH? I hope not.

Mrs Shih must have heard me ;o-)

Why has there been no RNS announcing the results of the AGM? Mrs Shih is usually very efficient in arranging that and it usually gets issued within an hour of the conclusion of the meeting.

I would not disagree 1pencil, I have been invested here for over 10 years, but have trimmed my holding - the biggest issue here is the financial and operational performance of the company has absolutely no correlation with the value of the company.

why would you be invested in a company and have no interest or regard to the share price?

when you have been invested for as long as I have, got to know the management, have been heavily invested and lost a lot of money you do tend to have emotions in the game. I've been positive and bullish for years and look where it has got me.

and what will happen when the EMA approves? I was in HK on the day Fruquintinib was approved - the share price dived

basically almost at the IPO price of 2016 after 6 years of stunning progress and a pipeline that's 10 times the size....unbelievable, the market is pricing in failure...what a complete joke

Interesting commentary regarding Amoy diagnostics and prognosis test deal with Hutchmed and AZ

https://talkmarkets.com/content/global-markets/week-in-review-wuhan-binhui-raises-47-million-for-oncolytic-virus-products?post=352478

yes good question 1pencil, Wuxi Bio, Innovent, Beigene, Legend ..... but generally we are down much more than most on the HFCAA lists Biotech and non-Biotech

yes I fully get the shorting process (I invested in Quindell so I know it well) - what I am interested in is why no one has covered yet